Fate Therapeutics Wins FDA IND Clearance for FT839, a Dual-CAR T-Cell Therapy for Autoimmune Disease

Fate Therapeutics has received FDA clearance of its Investigational New Drug (IND) application for FT839, an off-the-shelf, induced pluripotent stem cell (iPSC)-derived CAR T-cell product candidate engineered to simultaneously target CD19 and CD38. The company describes FT839 as the first dual-CAR T-cell therapy designed for comprehensive elimination of pathogenic immune cells across complex, multi-system autoimmune disorders, distinguishing it from single-antigen CAR-T approaches that have so far focused primarily on CD19-expressing B cells.

What makes FT839's dual-CAR design different?

The choice to co-target CD19 and CD38 is mechanistically deliberate. CD19 captures most B cells, but autoimmune disease is also driven by long-lived plasma cells, which downregulate CD19 as they mature and are often missed by CD19-only approaches. CD38 is broadly expressed on plasma cells, meaning FT839's dual-CAR design is intended to eliminate both the B-cell precursors and the mature, autoantibody-producing plasma cells that a single-antigen therapy would allow to persist.

FT839 carries 13 genetic edits and is manufactured as a uniform drug product from a clonal master iPSC line, an approach intended to eliminate the batch-to-batch variability associated with patient-derived, autologous CAR-T manufacturing.¹ Fate has not detailed the full set of edits in this release, but its iPSC platform has historically combined edits for antigen targeting, persistence, and immune evasion within a single engineered cell line. FT839 also incorporates an hnCD16 Fc receptor and a CD3 fusion receptor, features the company says allow it to synergize with monoclonal antibodies and T-cell engagers to broaden the range of pathogenic immune cell types it can eliminate.

Why skip conditioning chemotherapy?

A central feature of FT839's design is its intended ability to eliminate pathogenic immune cells without requiring conditioning chemotherapy, a step conventionally used ahead of CAR-T infusion to deplete existing immune cells and reduce rejection risk. Removing that requirement could meaningfully change the risk-benefit calculation for autoimmune indications, where the toxicity of conditioning regimens has limited CAR-T's use outside of hematologic malignancy to date.

Bob Valamehr, Ph.D., MBA, president and chief executive officer of Fate Therapeutics said in a press release: "FDA clearance of the FT839 IND is an important milestone that expands our off-the-shelf, iPSC-derived CAR T-cell platform capabilities for the comprehensive treatment of autoimmune disease, including rheumatoid arthritis. By co-targeting CD19 and CD38, FT839 is uniquely engineered to eliminate the full spectrum of aberrant, disease-driving immune cells, including B cells, plasma cells, and activated T cells, that are often the foundation of multicellular disease found in many autoimmune disorders as well as in hematological malignancies. In addition to the incorporation of multiple genetic edits to enhance performance and safety of the drug product, FT839 also includes our patented Sword & Shield™ technology which is designed to support durable activity without dependence on conditioning chemotherapy."

Preclinical data presented at the 2025 American Society of Hematology (ASH) Annual Meeting supported this rationale, demonstrating FT839's dual-CAR mechanism could specifically eliminate a variety of pathogenic immune cell types relevant to both autoimmune disease and hematologic malignancy.

What does the clinical path look like?

With IND clearance secured, Fate Therapeutics plans to advance FT839 into a basket clinical trial spanning multiple autoimmune diseases, administered in combination with standard-of-care therapy. Enrollment in the phase 1/2 study is expected to begin in the second half of 2026. The basket trial design, evaluating a single product candidate across several distinct autoimmune indications rather than one disease at a time, reflects a broader shift toward platform-level cell therapy development that companies are also pursuing in allogeneic and in vivo CAR-T programs elsewhere in the field.²

How does FT839 fit Fate's broader pipeline?

FT839 builds on the iPSC platform behind FT819, Fate's CD19-directed CAR T-cell candidate and the first-ever CAR-T therapy derived from a clonal master iPSC line. FT819 is furthest along in Fate's autoimmune pipeline, with preliminary clinical data in systemic sclerosis scheduled for presentation at the ISSCR 2026 Annual Meeting. Together, the two programs position Fate among a small group of companies applying iPSC-derived, off-the-shelf CAR-T manufacturing specifically to autoimmune disease rather than oncology alone, an area that has drawn increasing industry attention following early remission signals reported by other allogeneic CAR-T developers in conditions such as lupus.³

References

1. Fate Therapeutics Receives FDA Clearance of Investigational New Drug Application for FT839 Product Candidate. (2026 Jul 9). Globe Newswire. https://www.globenewswire.com/news-release/2026/07/09/3324792/24675/en/fate-therapeutics-receives-fda-clearance-of-investigational-new-drug-application-for-ft839-product-candidate.html?_gl=1*40cpyl*_up*MQ..*_ga*MjEwMTI1NzExOC4xNzgzNjIyMDUz*_ga_B6167QB2TF*czE3ODM2MjIwNTMkbzEkZzAkdDE3ODM2MjIwNTMkajYwJGwwJGgxNTI4NjkyODY.*_ga_ERWPGTJ5X8*czE3ODM2MjIwNTMkbzEkZzAkdDE3ODM2MjIwNTMkajYwJGwwJGgw. July 9, 2026.
2. Schoenthaler, E. (2026 Jun 11). Imviva Reports High Response Rates for Off-the-Shelf CAR-T Therapy CTD402 in Relapsed or Refractory T-ALL/LBL. BioPharm International. https://www.biopharminternational.com/view/imviva-reports-high-response-rates-for-off-the-shelf-car-t-therapy-ctd402-in-relapsed-or-refractory-t-all-lbl
3. The BioPharm Brief: Oncology Momentum, CAR-T Advances, Strategic Expansion. (2026 May 15). BioPharm International. https://www.biopharminternational.com/view/imviva-reports-high-response-rates-for-off-the-shelf-car-t-therapy-ctd402-in-relapsed-or-refractory-t-all-lbl